Novartis: to buy anti-inflammatory drug firm IFM Tre
(CercleFinance.com) - Novartis plans to buy IFM Tre, a subsidiary of US-based immunotherapy company IFM Therapeutics focused on developing anti-inflammatory medicines, the Swiss drugmaker said on Monday.
The acquisition will give Novartis full rights to IFM Tre's portfolio of NLRP3 inhibitors, that play a critical role in the body's innate immune system, it said.
In particular, the deal will give Novartis one clinical and two pre-clinical programs targeting the NLRP3 inflammasome, which serves as a danger sensor for pathogens like bacteria and viruses.
Novartis said this pathway is a potentially potent approach for treating several metabolic, fibrotic, autoimmune, and neurological diseases.
Under the terms of the agreement, Novartis will acquire all of IFM Tre's shares in issue, which will receive an upfront payment and will be eligible for milestone payments.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The acquisition will give Novartis full rights to IFM Tre's portfolio of NLRP3 inhibitors, that play a critical role in the body's innate immune system, it said.
In particular, the deal will give Novartis one clinical and two pre-clinical programs targeting the NLRP3 inflammasome, which serves as a danger sensor for pathogens like bacteria and viruses.
Novartis said this pathway is a potentially potent approach for treating several metabolic, fibrotic, autoimmune, and neurological diseases.
Under the terms of the agreement, Novartis will acquire all of IFM Tre's shares in issue, which will receive an upfront payment and will be eligible for milestone payments.
Copyright (c) 2019 CercleFinance.com. All rights reserved.